Alerta

CANCER THERAPY COMPOSITIONS AND USES THEREOF

Absstract of: US20260048108A1

The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject. Compositions described herein include lipid carriers, optionally including an inorganic particle, capable of admixing with nucleic acids. Nucleic acids provided herein include those encoding for cancer antigens (full length proteins or fragments) as well as antibodies. Methods of using the compositions as a therapeutic vaccine for the treatment of a cancer are also provided.

ULTRASOUND-ASSISTED DELIVERY OF DRUG-LOADED CHITOSAN NANOPARTICLES

Absstract of: US20260048127A1

The present invention, based on a non-bubble-based sonoporation technique, provides an ultrasound-assisted delivery platform for drug-loaded chitosan nanoparticles. This platform comprises: the administration of drug-loaded chitosan nanoparticles and the application of ultrasound stimulation. The drug-loaded chitosan nanoparticles are delivered to a target site, where ultrasound waves are directly applied to induce cellular membrane deformation. The ultrasound mechanical force temporarily alters membrane permeability, thereby facilitating the intracellular delivery of the drug-loaded chitosan nanoparticles.

NOVEL ANTIGENS FOR CANCER AND USES THEREOF

Absstract of: US20260048105A1

Breast cancer is now the most prevalent cancer worldwide, and despite therapeutical advances in the last decades, metastatic breast cancer remains an incurable disease. Novel tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs) expressed by breast tumor cells are described herein. Synthetic long peptides, nucleic acids, compositions, cells, TCRs, antibodies and vaccines derived from these TSAs and TAAs are described. The use of the TSAs/TAAs, nucleic acids, compositions, antibodies, cells and vaccines for the prevention or treatment of breast cancer, including triple-negative breast cancer (TNBC), is also described.

LIPID NANOPARTICLE COMPRISING A DNA-BINDING PROTEIN

Absstract of: US20260048023A1

The present disclosure relates to lipid nanoparticles for delivery of DNA, the lipid nanoparticle comprising therein a DNA-binding protein or peptide bound to the DNA, and uses thereof.

ACID-RESPONSIVE POLYMER ADDITIVES INCREASE RNA TRANSFECTION FROM LIPID NANOPARTICLES

Absstract of: US20260048024A1

Lipid nanoparticles (LNPs) are widely used for RNA delivery but are limited by inefficient RNA release following endosomal escape. Disclosed herein are hybrid polymer-lipid nanoparticles (PLNPs) incorporating acid-responsive poly(lactic acid)-block-poly(carboxybetaine) zwitterionic polymers to enhance RNA delivery efficiency. The polymers are cationic at physiological pH to enable RNA complexation but become neutral at endosomal pH, reducing RNA binding affinity and promoting release. These polymers were integrated into clinically approved LNP formulations to form PLNPs. The resulting PLNPs showed up to a 5.4-fold decrease in siRNA IC50 values and a 4-fold increase in mRNA transfection across multiple cell lines. Enhanced cytosolic RNA levels were confirmed via confocal microscopy, with uptake and endosomal escape comparable to standard LNPs. The improvement in transfection efficiency was lost when acid-inert polymers were used, confirming the role of the acid-responsive polymers. This approach provides a versatile platform to improve RNA delivery from existing LNP systems.

Synthetic Nanostructures Including Nucleic Acids and/or Other Entities

Absstract of: US20260048010A1

Articles, compositions, kits, and methods relating to nanostructures, including synthetic nanostructures, are provided. Certain embodiments described herein include structures having a core-shell type arrangement; for instance, a nanostructure core may be surrounded by a shell including a material, such as a lipid bilayer, and may include other components such as oligonucleotides. In some embodiments, the structures, when introduced into a subject, can be used to deliver nucleic acids and/or can regulate gene expression. Accordingly, the structures described herein may be used to diagnose, prevent, treat or manage certain diseases or bodily conditions. In some cases, the structures are both a therapeutic agent and a diagnostic agent.

PHARMACEUTICAL FORMULATION WITH IMPROVED SOLUBILITY AND BIOAVAILABILITY

Absstract of: US20260048013A1

The present invention relates to a pharmaceutical formulation comprising at least one active pharmaceutical ingredient (API) having low aqueous solubility or a pharmaceutically acceptable salt thereof in the form of particles of a size between 1 and 800 nm, wherein said particles are encapsulated within a large microparticle of a size between 1 and 100 μm formed by a matrix comprising at least an excipient. Therefore, the API is entrapped or encapsulated in the microparticles of excipients. This pharmaceutical formulation contains the pharmaceutical active ingredient having improved solubility and subsequently supra-bioavailability.

INJECTABLE THERMOSENSITIVE HYDROGELS FOR A SUSTAINED RELEASE OF IRON NANOCHELATORS

Absstract of: US20260048005A1

Disclosed herein are injectable hydrogel formulations prepared by integrating crosslinked hyaluronic acid into Pluronic F127 for an extended release of DFO nanochelators. Methods of manufacture and of use are also provided.

NEUTRAL LIPID AND LIPID NANOPARTICLE

Absstract of: US20260048021A1

The present invention provides: a neutral lipid capable of suppressing the phase transition of endosomal membranes caused by phosphatidylcholine from being inhibited; and a lipid nanoparticle containing the neutral lipid. The present invention pertains to an ionic neutral lipid comprising a compound represented by general formula (I). In formula (I), R1 is a C1-22 hydrocarbon group; three R1 groups in one molecule may be the same as or different from each other; a1 and a2 are each independently an integer of 0 to 4; b1 and b2 are 0 or 1, satisfying b1+b2=1; R2 and R3 are each independently a hydrogen atom or a C1-3 alkyl group; and R4 is an anionic group.

METHOD AND SYSTEM

Absstract of: AU2024321749A1

A method of generating a plurality of different surface-decorated nanoparticles, decorated with different surface decoration, comprising: forming a plurality of microdroplets in a microfluidics device, each microdroplet comprising a nanoparticle and a respectively different macromolecule encoding a different surface decoration molecule; synthesising the surface decoration molecule, within each microdroplet, based on the macromolecule encoding the surface decoration molecule; conjugating the nanoparticle and the surface decoration molecule, within each microdroplet, to form surface decorated nanoparticles.

ANTIGEN CAPTURING NANOPARTICLE AND DENDRITIC CELLS FOR IN SITU CANCER IMMUNIZATION

Absstract of: WO2026039296A1

Compositions comprising migratory type 1 conventional dendritic cells in combination with a positively charged antigen capturing nanoparticle comprising a hydrophobic surface and use of the nanoparticle and dendritic cells optionally in combination with an immune checkpoint inhibitor in methods of treating cancer or preventing or reducing the risk of reoccurrence of a cancer in a subject.

ANALGESIC COMPOUNDS COMPRISING CHARGED PARTICLES AND METHOD OF MANUFACTURE THEREOF

Absstract of: WO2024216279A2

Disclosed herein is an analgesic composition comprising a nanoparticle and/or a microparticle that comprises a charged lipid and/or a supporting lipid; where the charged lipid comprises an electrically charged group. Disclosed herein too is a method of reducing joint inflammation, swelling and/or pain in a subject, the method comprising administering a therapeutically effective amount an analgesic composition to the subject; where the analgesic composition comprises a nanoparticle and/or a microparticle that comprises a charged lipid and/or a supporting lipid; where the charged lipid comprises an electrically charged group.

LIPID NANOPARTICLES FOR DELIVERY OF AGENTS

Absstract of: CN120936389A

The present disclosure provides compositions capable of delivering a load (including therapeutic agents, e.g., RNA) to organs or tissues other than the liver, lung and spleen (e.g., brain, heart, kidney and muscular tissue). More specifically, the composition comprises a plurality of lipid particles comprising an agent, a cationic lipid, and an ionizable lipid.

GENE EDITING FOR INTERVERTEBRAL, INTRA- AND PERIDISCAL THERAPY AND ASSOCIATED SPINAL DISORDERS

Absstract of: WO2024215956A1

The present disclosure provides compositions and methods for treating and preventing localized nociception, inflammation, or morphological changes associated with joint disease or illness, back or spine conditions or disorders, and musculoskeletal diseases or dysfunction.

MUCOSAL- AND CELL-MEMBRANE PENETRATING PEPTIDES AND USES THEREOF

Absstract of: AU2024249750A1

Peptides which are capable of penetrating mucosal membranes or cell membranes are provided. In some aspects, functionalized peptide conjugates are provided. Compositions of peptide conjugates are disclosed, and methods of using such compositions are provided.

COMPOSITION, VACCINE AND METHOD FOR TREATING INFLUENZA A

Absstract of: TW202444409A

The present disclosure provides a composition comprising a polymeric nanoparticle encapsulating an antigen and an agonist, wherein the antigen is M2e peptide. The composition may induce the immune response to influenza A. A method for inducing immune response to influenza A is also provided.

LIPID NANOPARTICLES FOR GENE EDITING SYSTEMS

Absstract of: WO2024215959A2

The present disclosure provides compositions and methods for treating and preventing localized nociception, inflammation, or morphological changes associated with joint disease or illness, back or spine conditions or disorders, and musculoskeletal diseases or dysfunction with an LNP-encapsulated CRISPR/Cas9 gene editing system.

LYME DISEASE VACCINES

Absstract of: WO2024215721A1

This disclosure provides methods and compositions related to messenger ribonucleic acid (mRNA) vaccines for Lyme disease and related methods of prevention. The mRNA vaccines comprise an mRNA comprising an open reading frame(s) encoding for a protein comprising a Borrelia outer surface protein A (OspA) extracellular domain. In some aspects of the disclosure, the mRNA vaccines comprise mRNA polynucleotides collectively encoding for at least seven different Borrelia outer surface protein A (OspA) extracellular domains.

LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF

Absstract of: AU2024251515A1

The present application relates to lipid nanoparticles containing a steroid compound, and the preparation and a use of the lipid nanoparticles. The lipid nanoparticles can be used to deliver effective loads (such as a nucleic acid) into non-liver organs such as the spleen for the treatment or prevention of certain diseases or conditions, particularly spleen-associated diseases.

LIPID NANOPARTICLES TARGETING SPLEEN

Absstract of: EP4696305A1

The present application relates to lipid nanoparticles comprising steroid compound, as well as the preparation and uses of such lipid nanoparticles. Such lipid nanoparticles are useful in the delivery of payloads, such as nucleic acids, in vivo to non-hepatic organs (e.g., spleen) for the treatment or prevention of certain diseases or disorders, particularly spleen diseases.

PREPARATION METHOD FOR NANOBODY TARGETING TISSUE FACTOR AND CONJUGATE AND USE THEREOF

Absstract of: EP4696714A1

Disclosed are a new nanobody (Nb) targeting a tissue factor (TF) and a nanobody-drug conjugate (NDC), a preparation method therefor and the use thereof. The monoclonal nanobody and the corresponding NDC can efficiently and high-specifically bind to a purified TF protein and a TF on the surface of various TF abnormally expressed tumor cells, have a high affinity and a low immunogenicity, and have a significant anti-tumor effect in vivo and in vitro.

POLYSIALIC ACID-POLYMER CONJUGATE AND NANOPARTICLE

Absstract of: MX2025012226A

Disclosed herein is a polysialic acid (PSA)-polymer conjugate compound represented by the structural formula (I): or a pharmaceutically acceptable salt thereof, wherein P is a poly(lactide-co-glycolide)-poly(ethylene glycol) copolymer (PLGA-PEG) and p is an integer from 4 to 200, nanoparticles comprising same, and methods of treating ophthalmic diseases using same.

NANOPARTICLES OF MYCOPHENOLIC ACID PRODRUG MOLECULES AND THERAPEUTIC USE THEREOF

Absstract of: AU2024255212A1

A nanoparticle is described, which comprises a plurality of therapeutic molecules arranged in the form of a spherical micelle, suitable for the localized delivery and release of mycophenolic acid, and therefore effective in the treatment of autoimmune diseases, fibrotic diseases and/or organ rejection diseases, in particular of the lungs. A pharmaceutical composition comprising the nanoparticle in a pharmaceutically acceptable vehicle, and a method for manufacturing said nanoparticle are also described.

METHODS AND COMPOSITIONS FOR DENDRITIC CELL TARGETING VACCINES

Absstract of: AU2024250699A1

The present disclosure provides novel compounds, methods, and cell targeting mRNA vaccine formulations for targeted delivery, such as delivery to dendritic cells. The compound and formulation provided herein are designed to have a targeting moiety configured to provide selective delivery features specific for dendritic cells and a lipid tail for incorporated into the bilayer membrane of the formed lipid nanoparticle.

一种靶向CLL-1的嵌合抗原受体NK细胞及其制备方法和应用

Nº publicación: CN121538177A 17/02/2026

Applicant:

上海鲁奥生物工程技术有限公司

Absstract of: CN121538177A

本发明公开了一种靶向CLL‑1的嵌合抗原受体NK细胞及其制备方法和应用，属于生物医药技术领域。本发明提供的脐带血来源的靶向CLL‑1的嵌合抗原受体NK细胞，其实现了对目标细胞的精准识别，且相关移植物抗宿主病风险较低。本发明采用脂质纳米颗粒递送CAR mRNA，实现了对脐带血NK细胞的高效、安全转染。通过将所述CAR‑NK细胞与NKG2A抑制剂联合使用，可有效阻断由肿瘤细胞表面HLA‑E分子上调所介导的免疫抑制信号，显著增强CAR‑NK细胞对肿瘤的清除能力，为解决多药耐药型急性髓系白血病治疗过程中的适应性耐药问题、提升疗效持久性提供了有效的组合策略。